Exhalo
Relief - Migraine Tracker
Snapshot
Publisher DNA
What defines Exhalo?
AI intelligence is not yet available for Exhalo. The portfolio data below is up to date.
Portfolio
What does Exhalo ship?
Apps
6 apps analysed
Analysis in progress
Camera-based measurement removes hardware barriers
- Apple Health integration enables data portability
- AI-driven semantic analysis provides deeper psychological insights than manual entry competitors
Analysis in progress
Analysis in progress
Distributed across 6 markets, strongest in Europe.
Based on 2 of 6 apps with localized market data, more coverage rolling in as scans complete · last scanned .
Americas (2)
- United States2 / 2
- Brazil1 / 2
Europe (4)
- France1 / 2
- Germany1 / 2
- Portugal1 / 2
- Spain1 / 2
Core markets (2/2 apps)
Rivals
Who does Exhalo compete with?
The rivals identified
Nemeses(1)
EMMO dominates the lifestyle journaling space with a massive user base and high-frequency engagement, directly competing for the same emotional-tracking demographic as Mental Note.
Contenders(2)
This app targets the 'legacy' journaling market, focusing on physical-world preservation and long-term narrative archiving.
Shine competes by visualizing emotional trends over time, appealing to users interested in data-driven self-reflection.
Same space(4)
It competes by using AI to conduct 'interviews' with the user, guiding the journaling process through active questioning.
This app focuses on the intersection of AI and autobiography, competing for users interested in long-form narrative generation.
This app positions journaling as a self-care chat experience, competing for the mental health and wellness segment.
Ondo is a direct feature-set competitor, utilizing conversational AI to facilitate journaling and memory retrieval.
New entrants(2)
Lore disrupts the market by integrating directly with messaging apps to extract stories, bypassing the need for manual entry.
This newcomer introduces a unique 'newspaper' format for family journaling, challenging our individual-centric model.